LIPORASE HYALURONIDASE 10 VIALS
Pharmaceutical-grade Hyaluronidase (1,500 IU/vial) for rapid, targeted degradation of synthetic Hyaluronic Acid fillers. Clinically validated to dissolve 98% of injected HA within 24 hours[1], ensuring precise correction and enhanced patient safety in aesthetic procedures.
Enzymatic Precision & Clinical-Grade Purity
Liporase utilizes highly purified recombinant Hyaluronidase, manufactured under GMP-certified conditions. The advanced enzymatic process ensures batch-to-batch consistency and a high activity rate (≥1,500 IU/vial), enabling rapid and selective hydrolysis of cross-linked synthetic Hyaluronic Acid. Laboratory assays confirm >98% substrate specificity, minimizing risk to endogenous HA and surrounding tissues.
Key Advantages
Rapid Filler Dissolution
Dissolves 98% of synthetic HA within 24 hours, enabling fast correction of overfilling or misplacement.
Selective Action
Targets only synthetic Hyaluronic Acid, preserving natural HA and minimizing adverse effects.
High Purity & Safety
GMP production ensures endotoxin-free, sterile vials with consistent enzymatic activity.
Versatile Clinical Use
Effective for correcting overfilling, vascular compromise, and uneven filler distribution.
Product Specifications
- Active Ingredient: Hyaluronidase 1,500 IU/vial
- Formulation: Lyophilized powder for reconstitution
- Packing: 10 vials/box
- Production Standard: GMP certified, ISO 13485
- Sterility: Terminal sterilization, endotoxin-free
- Storage: 2-8°C, protected from light
- Shelf Life: 24 months from manufacture date
Technology & Mechanism
- Enzyme Source: Recombinant Hyaluronidase
- Action: Hydrolyzes β-1,4 glycosidic bonds in synthetic HA
- Onset: Visible reduction of filler within 1–24 hours
- Specificity: >98% for cross-linked HA (in vitro data)
Professional Use Guidelines
Preparation
Reconstitute each vial with 1–2ml sterile saline. Use immediately after mixing. Inspect for particulate matter before administration.
Administration
Inject intradermally or subcutaneously at the site of unwanted filler. Dosage: 1,500 IU per 1ml of HA to be dissolved. Adjust based on clinical assessment.
Monitoring
Observe for immediate hypersensitivity. Assess filler reduction at 1–24 hours post-injection. Repeat if necessary, not exceeding recommended total dose.
Important Clinical Disclaimer
Notice: Clinical outcomes may vary due to individual patient factors and filler characteristics. All procedures must be performed by licensed medical professionals with emergency protocols in place.
Liporase is not intended for use in patients with known hypersensitivity to Hyaluronidase or severe allergies. Not for use in pregnancy or in areas of active infection. Immediate discontinuation is required if adverse reactions occur.
